Shahzad N. Raza

Shahzad N. Raza

Hematology Oncology | Hematology | Oncology
10201 Carnegie Avenue
Cleveland, OH 44106

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 143 publications

Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival.

Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival.

Journal: Annals of medicine
Published: August 07, 2026

Diagnostic Accuracy of Fat Pad Sampling and Bone Marrow Biopsy for AL Amyloidosis: A Systematic Review and Meta-Analysis.

Diagnostic Accuracy of Fat Pad Sampling and Bone Marrow Biopsy for AL Amyloidosis: A Systematic Review and Meta-Analysis.

Journal: Blood advances
Published: July 08, 2026

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

Real-world outcomes with BCMA- and GPRC5D-targeting bispecific antibodies in plasma cell leukemia.

Journal: Blood advances
Published: April 21, 2026

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Journal: Blood advances
Published: April 21, 2026

Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies.

Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies.

Journal: Transplantation and cellular therapy
Published: April 17, 2026

Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Response kinetics and depth of response after idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Journal: Blood cancer journal
Published: April 03, 2026

BIO26-048: A Meta-Analytic Evaluation of Efficacy and Safety Between Ide-cel and Cilta-cel in Relapsed/Refractory Multiple Myeloma Based on Clinical Trial and Real-World Data.

BIO26-048: A Meta-Analytic Evaluation of Efficacy and Safety Between Ide-cel and Cilta-cel in Relapsed/Refractory Multiple Myeloma Based on Clinical Trial and Real-World Data.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 31, 2026

Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy.

Smoldering Multiple Myeloma: Early Intervention or Structured Surveillance? A Comprehensive Review of Evidence for and Against Early Therapy.

Journal: Cancers
Published: March 18, 2026

Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up.

Fully human BCMA CAR-T therapy in multiple myeloma: lessons from long-term follow-up.

Journal: Translational cancer research
Published: February 23, 2026

The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.

The Safety and Efficacy of Commercial BCMA-Directed CAR T-Cell Therapy in Systemic AL Amyloidosis With Concurrent Myeloma.

Journal: American journal of hematology
Published: February 20, 2026

Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention.

Multiple Myeloma Screening Education: A Community-Based Health Literacy Intervention.

Journal: Cancer research communications
Published: January 20, 2026

Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023.

Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023.

Journal: EJHaem
Published: January 19, 2026
Showing 1-12 of 143

Last Updated: 09/26/2026